Skip to main content
. 2023 Jan 13;21:100586. doi: 10.1016/j.ebr.2023.100586

Table 1.

Patient characteristics.

Variable Number (%) or mean (SD) [range]
All 123(100)
   Female 43 (35.0)
   Male 80 (65.0)
Age 48.0 (16.8)[20–86]
Other disease
   Somatic 49 (39.8)
   Psychiatric 21 (17.1)
   Somatic and/or psychiatric 61 (49.6)
First symptom
   Epilepsy 87 (70.7)
   Other 35 (28.5)
   Incidental finding 1 (0.8)
   Previous epilepsy 2 (1.6)
Tumor location
   Frontal 53 (43.1)
   Temporal 18 (14.6)
   Parietal 11 (8.9)
   Occipital 3 (2.4)
   Several lobes/large 38 (30.9)
Tumor grade
   2 49 (39.8)
   3 19 (15.4)
   4 55 (44.7)
IDH mutation
   Yes 53 (43.1)
   No 62 (50.4)
   Unknown 8 (6.5)
Seizure type*
   Focal aware 65 (52.8)
   Focal impaired awareness 36 (29.3)
   Focal to bilateral tonic-clonic 87 (70.7)
   Other 0
Histopathological diagnosis
   Astrocytoma 29 (23.6)
   Oligoastrocytoma 24 (19.5)
   Oligodendroglioma 15 (12.2)
   Glioblastoma 55 (44.7)
Change to more malignant during follow-up** 15 (12.2)
Progression during follow-up *** 75 (61.0)
Tumor treatments during follow-up
   Resection 108 (87.8)
   Biopsy 19 (15.4)
   Radiotherapy 71 (57.7)
   Chemotherapy 85 (69.1)
   Chemoradiotherapy 59 (48.0)
Death during follow-up
   Yes 67 (54.5)
   No 56 (45.5)

*Several seizure types were possible in the same patient.

**Histopathological verification.

***During treatment leading to a change of treatment or after a stable post-treatment period.